

Remarks

Claims 24-30 and 32-34 are pending.

The specification has been amended as requested by the Examiner.

No issues of new matter should arise and entry of the amendment is respectfully requested.

Objection to Specification: Office Action at Page 4

The specification has been amended as requested by the PTO. In view thereof, Applicants respectfully request that this objection be withdrawn.

Obviousness-Type Double Patenting Rejections

Applicants are filing herewith Terminal Disclaimers over US Patent No. 7,671,023 and US Patent No. 7,879,794. Applicants respectfully request that these rejections be withdrawn.

Claims 24-30 and 32-34 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 20-23 and 26 of copending Application No. 12/641,733; claims 19, 20 and 39-51 of copending Application No. 12/295,259; and claims 1, 2, 4-7, 9-13 and 15-20 of copending Application No. 12/055,147.

With entry of this amendment and terminal disclaimers, the sole remaining rejections are provisional obviousness-type double patenting rejections over claims in copending applications. In view thereof, Applicants submit the instant application is in condition for allowance.

Response and Amendment under 37 CFR § 1.111

US Application No. 10/589,054

Page 4 of 4

Conclusion

Applicants respectfully submit that Claims 24-30 and 32-34 are in condition for allowance.

Dated: *August 3, 2011*

Respectfully submitted,
AMYLIN PHARMACEUTICALS, INC.

Belinda Lew

Belinda Lew, Ph.D.
Registration No. 53,212

AMYLIN PHARMACEUTICALS, INC.
9360 Towne Centre Drive
San Diego, CA 92121
Phone: 858-552-2200
Direct Dial: 858-754-4230